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Abstract Monoclonal antibody 4C1 specifically binds to and
neutralizes the most potent neurotoxin (AahII) of the scorpion
Androctonus australis. The cDNAs encoding the variable regions
of this antibody were isolated by PCR-mediated cloning. A
single-chain Fv gene was engineered and expressed in Escherichia
coli. The recombinant protein had neutralizing activity similar to
that of the intact antibody in vitro and in vivo. We have thus
neutralized the pharmacological and biological properties of a
scorpion neurotoxin with a single-chain Fv, which opens new
perspectives for the treatment of envenomizations.
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1. Introduction
Antivenom serotherapy was ¢rst reported in 1894 and anti-
venoms are still the only speci¢c treatment for scorpion stings
[1]. However, such treatment has several limitations. Antive-
noms are usually heterologous polyclonal immunoglobulins or
F(abP)2 fractions from immunized animals [2]. They are di⁄-
cult to prepare reproducibly, even under standardized condi-
tions, and their neutralizing properties may vary from one
batch to another. Heterologous antibodies and F(abP)2 mole-
cules have much shorter half-lives in human plasma than hu-
man IgG and do not di¡use easily from the vascular compart-
ment [3]. This could probably be slightly improved by using
Fab fragments, but they can still produce adverse e¡ects in-
volving allergic hypersensitivity [4]. Monoclonal antibodies
may o¡er substantial advantages in terms of potency, repro-
ducibility and freedom from contaminants but they are not
easy to use. The production of human monoclonal antibodies
often has problems, mostly related to the instability of the
hybridoma cell line, and the therapeutic use of murine mono-
clonal antibodies which is sometimes e¡ective under labora-
tory conditions is at present not economical [5,6]. One way of
avoiding most of these problems is to engineer novel recombi-
nant antigen binding proteins that have increased e⁄ciency
and new properties. Fv fragments, which are the minimal
structure likely to retain the binding characteristics of an anti-
body, can now be produced in heterologous systems [7,8]. The
recombinant variable domains (VH and VL) are genetically
linked in a single-chain (scFv) construct via a short £exible
peptide that connects the C-terminus of one domain (VH) to
the N-terminus of the other (VL) [9]. This stabilizes their as-
sociation. scFvs can be derived from hybridoma or combina-
torial antibody libraries by phage display technology [10,11]
and may be very useful in many ¢elds, such as research, im-
munodiagnosis and immunotherapy [12^14]. scFvs are cleared
more rapidly from the blood to extravascular spaces than the
much larger IgGs, F(abP)2 and Fab molecules, resulting in
better tissue penetration [15^17]. Thus, scFvs are potentially
very useful molecules for treating cancer and detoxication [18^
20]. The small size of the scFv permits their rapid di¡usion in
the body for detoxication and the fast in vivo clearance of
immunocomplexes via the urine. This minimizes the chance of
late release of bound toxin and the reemergence of toxicity.
Lastly, the absence of the immunoglobulin constant domains
decreases the risk of an immunological response from the
patient.
Hybridoma 4C1 secretes a high a⁄nity murine monoclonal
antibody directed against the main toxic component (AahII)
of the venom from the North African scorpion Androctonus
australis hector. AahII is a 64 amino acid residue polypeptide
that is highly toxic to mammals because it interacts with po-
tential-dependent sodium channels [21,22]. Antibody 4C1 can
competitively neutralize the toxin binding to its receptor be-
cause the epitope overlaps or is close to the receptor binding
region of the toxin [23]. This report describes the engineering
of an scFv derived from antibody 4C1 which is e⁄ciently
produced by recombinant bacteria in a soluble, active form.
The scFv 4C1 can neutralize the pharmacological and biolog-
ical e¡ects of the toxin.
2. Materials and methods
2.1. Cell lines, Escherichia coli strain and vectors
The mouse hybridoma cell line 4C1 secreting a monoclonal anti-
body directed against the scorpion toxin AahII was originally pro-
duced by Bahraoui et al. [23]. Here, hybridoma cells were cloned once
by limiting dilution. Control tests were done with clone 4C1(BC5)
expanded in BALB/c mice. The secreted immunoglobulins were puri-
¢ed on protein-A Sepharose (Pharmacia) [24]. Antigen-mediated ELI-
SA was used to determine the heavy chain isotype (Sigma ISO-2 kit),
and the light chain isotype (rat monoclonal antibodies anti-mouse
kappa or lambda chain from Sigma).
E. coli HB21 51 transformed with plasmid pHEN1A58(Ile)scFv was
used to produce the irrelevant scFvA58 protein directed against an
epitope of scorpion hemocyanin [10].
The MRC-OX74 antibody directed against the peptide £ag
VASDPPVTITNPAT was a gift from Dr. N. Barclay [25]. E. coli
strain JM109 (Promega, Lyon, France) was used as the cloning host
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and strain HB2151 as the gene expression host. pGEMT (Promega,
Lyon, France) was used for cloning and sequencing hybridoma-de-
rived immunoglobulin variable regions. The scFv gene was ligated and
expressed in the pHEN1 phagemid kindly provided by Dr. G. Winter
[26].
2.2. Cloning of cDNAs encoding the variable regions of antibody 4C1
Total RNA was prepared from 107 freshly subcloned hybridoma
4C1(BC5) cells using the RNAnow kit (Biogentex, USA) and ¢rst
strand cDNA was synthesized using an oligodT12ÿ18 primer [10].
The VH and VL chain domains were ampli¢ed by PCR with primers
designed after analysis of the Kabat data base [27]. VH was ampli¢ed
with the forward primer MHFor (5P-CGG GAT CCT CTA GAC
AGT GGA TA(GA) AC(AC) GAT GG-3P) complementary to the
CH1 domain of the Q chain and the reverse primer MHRev (5P-
ATG AAC TTC GGG CTC AGC TTG ATT TT-3P) complementary
to the Q chain sequence leader. The primers to amplify VL were
MKCFor (5P-GGA TAC AGT TGG TGC AGC ATC-3P) which hy-
bridizes to the U light chain constant domain and MKRev (5P-ATG
AAG TTG CCT GTT AGG CTG TTG GTG CT-3P), which hybrid-
izes to the light chain sequence leader. The 50 Wl PCR mixtures con-
tained 50 ng hybridoma cDNA, 20 pmol of each appropriate primer,
250 WM of each dNTP, 1UTaq bu¡er (Promega, Lyon, France) and
1 U Thermus aquaticus (Taq) polymerase. Ampli¢cation included 25
cycles of 1.5 min at 94‡C, 2.5 min at 55‡C and 3 min at 72‡C in a
thermocycler (PTC-150, MJ Research). The ampli¢ed DNAs were
ligated into the pGEMT vector and the recombinant plasmids puri¢ed
by alkaline lysis. The DNA sequences of the cloned VH and VL inserts
were determined using the PRISM Cycle Sequencing kit (ABI) and
M13 Forward and Reverse primers. The sequences of the V genes
were determined on two independent batches of RNA preparations
to ensure accuracy. The sequences were analyzed with the programs
from the University of Wisconsin Genetics Computer Group.
2.3. Construction and cloning of scFv-4C1 for expression in bacteria
A synthetic gene encoding scFv-4C1 was ampli¢ed by overlap ex-
tension using Pyrococcus furiosus (Pfu) polymerase (Stratagene, La
Jolla, CA, USA) [10]. The genes encoding the variable domains
were independently modi¢ed in an initial PCR ampli¢cation. The
modi¢cations at their 5P and 3P extremities were with primers
MH2Rev (5P-CCG GCC ATG GCC GAA GTG CAT CTG GTG
GAG-3P) and LinkFor (5P-ACC ACC GGA TCC GCC TCC GCC
TGA AGA GAC AGT GAC CAG AGT CC-3P) for the VH and
LinkRev (5P-GGA GGC GGA TCC GGT GGT GGC GGA TCT
GGA GGT GGC GGA AGC GAT GTT (C,T)TG ATG ACC CA-
3P) and FlagFor (5P-AGT AGC TCG AGC TAT GTC GCA GGA
TTA GTT ATA GTG ACA GGA GGG TCA CTG GCT ACT TTG
ATT TCC AGC TTG GT-3P) for the VL domain. The four primers
were designed to not introduce any mutation into the deduced peptide
sequences of antibody 4C1 variable domains. Primers LinkFor and
LinkRev carried overlapping sequences encoding the linker peptide
(Gly4Ser)3. Primer MH2Rev carries an NcoI site suitable for cloning
in the plasmid pHEN1. Primer FlagFor encoded the C-terminal Flag
peptide tail recognized by antibody MRC-OX74. It carries a stop
codon followed by a restriction sites (XhoI) suitable for cloning.
The modi¢ed VH and VL genes were mixed together and reampli¢ed
in a second round of PCR with the external primers MH2Rev and
FlagFor. The resulting PCR product was puri¢ed, cleaved successively
with NcoI and XhoI and inserted in frame with the PelB leader se-
quence into the pHEN1 vector linearized with the same restriction
enzymes. The recombinant vector (pHEN1-4C1) was electroporated
into competent HB2151 cells and positive clones were selected upon
PCR ampli¢cation with appropriate primers. The entire DNA se-
quence of the cloned scFv insert was veri¢ed on both strands using
sequencing primers adjacent to the NcoI and XhoI sites of pHEN1.
2.4. Bacterial expression of scFv-4C1
Non-suppressive HB2151 E. coli cells transformed with the scFv
expression vector were grown as in [13]. Bacteria were induced for
production of the scFv-4C1 protein with 0.5 mM isopropyl L-D-thio-
galactoside for up to 72 h at temperatures of 16^30‡C. The cells were
harvested by centrifugation at 4000Ug for 10 min at 4‡C. Proteins
released into the culture supernatant were precipitated with ammo-
nium sulfate (60%) and resuspended in 25 mM HEPES pH 7.4 (5% of
the initial volume). Soluble periplasmic proteins were extracted as in
[13]. These preparations were then extensively dialyzed against 25 mM
HEPES pH 7.4 bu¡er and clari¢ed by centrifugation (15 000Ug, 4‡C,
45 min). The solutions were concentrated 5-fold with a Centricon 30
(Millipore) and then passed through an 0.2 Wm pore size membrane
(Sartorius, Goºttingen, Germany).
The production of the recombinant protein was monitored by
Western blot [28,29] which was detected by the peptide £ag with
monoclonal antibody MRC-OX74 [10].
2.5. Detection of scFv 4C1 activity
2.5.1. Protein concentration. The protein contents of synaptosome
or scFv preparations were determined with the Micro BCA protein
assay reagent (Pierce).
2.5.2. Radioimmunoassays (RIA). The binding of scFv prepara-
tions to [125I]AahII was assessed. [125I]AahII was prepared and puri-
¢ed [30]. Successive dilutions of IgG or scFv preparations were mixed
with [125I]AahII (1U10310 M ¢nal concentration) in PBS-0.1% BSA
(¢nal volume: 150 Wl) and incubated for 90 min at 37‡C and then
overnight at 4‡C. Bound was separated from free antigen by adsorb-
ing the free antigen onto activated charcoal. A suspension of 1.6%
charcoal (Sigma) and 0.16% dextran T-70 (Sigma) in PBS-0.2% BSA
was added to each tube (0.5 ml) and the mixtures were incubated for
30 min at 4‡C, then centrifuged at 9000Ug for 10 min. The radio-
activity in the supernatants was measured with a gamma counter
(Packard Crystal II). All assays were conducted in duplicate. IgG
4C1 (1U10310 M) or scFv 4C1 preparation (1/18 ¢nal dilution)
were mixed with [125I]AahII (1U10310 M) plus various concentrations
of unlabeled AahII for competitive experiments.
2.5.3. Neutralization assays
2.5.3.1. Receptor binding assay. Rat brain synaptosomal fraction
was prepared [31,32]. Binding assays were performed in 140 mM
choline chloride, 5.4 mM KCl, 0.8 mM MgCl2, 1.8 mM CaCl2, 25
mM HEPES and 0.1% BSA at pH 7.4. [125I]AahII (1U10310 M) was
incubated with dilutions of IgG or scFv preparations for 90 min at
37‡C. Synaptosomal preparation was added (0.4 mg/ml) and the in-
cubation was continued for 30 min at 37‡C. The mixtures were cen-
trifuged at 9000Ug and washed three times. The radioactivity in the
pellets was measured. All assays were conducted in duplicate.
2.5.3.2. Assays in vivo. The neutralizing capacity of scFv-4C1
preparations was tested by the intracerebroventricular (i.c.v.) route.
Amounts of AahII equal to or greater than the lethal dose were
incubated for 90 min at 37‡C and 30 min at 4‡C with an equal volume
of scFv preparation. The mixture was then injected into female
C57BL/6 mice of 20 g weight (groups of six) by the i.c.v. route.
Surviving mice were recorded after 24 h.
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Fig. 1. Construction and expression of the scFv-4C1 chimeric gene.
a: Molecular cloning of scFv-4C1. VH (1) and VL (2) domains were
ampli¢ed by RT-PCR from hybridoma 4C1 RNA using external
primers complementary to the leader sequence and constant do-
mains. scFv gene (3) was assembled by splicing by overlap extension
PCR with speci¢c primers deduced from VH and VL sequences.
Products were visualized on an agrose gel (1%). M, 100 bp DNA
ladder. b: Production of the scFv-4C1 protein. Periplasmic (1, 3)
and culture supernatant (2, 4) fractions (25 Wg) of bacteria not in-
duced (1, 2) or induced at 16‡C for 48 h (3, 4) were analyzed by
Western blot using the anti-£ag MRC-OX74 antibody. M, molecu-
lar size marker in kDa.
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3. Results
3.1. Construction and sequence of the scFv-4C1 gene
Antibody 4C1 was shown to be an IgG1 (kappa chain). To
generate an scFv fragment, the VH and VL genes were cloned
from cDNA and joined by a sequence encoding the £exible
(Gly4-Ser)3 linker in a PCR ampli¢cation (Fig. 1a). The re-
sulting DNA was inserted into the bacterial expression vector
pHEN1. The sequences of the VH and VL domains assembled
in the scFv chimeric gene were the same as those obtained
after cloning VH and VL in pGEMT (Fig. 2). The primers
used to construct the scFv gene were designed so that they
perfectly matched the ends of the variable region cDNAs.
This is important because mutations induced by the VH 5P
primer could in£uence the activity of the recombinant anti-
body [33,34]. No mutation was introduced by the Pfu DNA
polymerase which was selected for the assembling PCR am-
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Fig. 2. The nucleotide and predicted amino acid sequences of the AahII-speci¢c scFv-4C1. The nucleotide sequences corresponding to the re-
striction sites NcoI and XhoI used for cloning, the linker peptide (Gly4Ser)3 and the peptide £ag are shown in italics. The deduced amino acid
sequence of the complementary determining regions (CDRs) of VH and VL are underlined.
Table 1
In vivo neutralization of AahII toxicity in C57BL/6 mice by scFv
preparations
AahII injected (ng) scFv preparation
4C1 A58
1.50 4/6
2.25 1/6
3.00 6/6 0/6
3.75 6/6
4.50 4/6
6.00 3/6
7.50 0/6
AahII solutions were incubated with AahII-speci¢c scFv (4C1) or
with irrelevant scFv (A58) before i.c.v. injection into mice. The
LD50 of the toxic fraction in the absence of antibody was 1.5 ng
per 20 g mouse. Results are expressed as the number of surviving
mice/injected mice.
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pli¢cation because it has the lowest error rate of any thermo-
stable DNA polymerase tested to date [35].
Comparison of the current sequence with those in the im-
munological database of Kabat [27] indicated that the VH
region of antibody 4C1 belonged to the mouse heavy chain
family XIV subgroup IIID, whereas the VL regions belonged
to the mouse U light chain family IV subgroup I. Comparison
of the deduced amino acid sequence with those of the immu-
noglobulin variable regions stored in the SwissProt data bank
also permitted identi¢cation of the hypervariable regions or
CDRs forming the antigen binding loops of the antibody. The
cDNA sequences of antibody 4C1 VH and VL are now regis-
tered in the EMBL data bank (accession numbers Y17588 and
Y17589).
3.2. Production of recombinant scFv protein
Recombinant bacteria in the exponential growth phase were
induced at di¡erent temperatures. The scFv accumulated in
the cytoplasm, mainly as inclusion bodies, whatever the in-
duction time or temperature (data not shown). However, the
presence of the PelB signal peptide allowed production of
small amounts of the scFv protein which was found in the
periplasm of bacteria harboring the pHEN1-4C1 vector. It
was detected in cells induced at 16‡C for 48^72 h (Fig. 1b).
The intact recombinant scFv was even released into the cul-
ture medium under these conditions and no degradation prod-
ucts were detected. This procedure provided enough material
for us to evaluate the activity of scFv.
3.3. Immunoreactivity and speci¢city of scFv preparations
for toxin AahII
scFv 4C1 recognized AahII in an RIA (Fig. 3a). The spe-
ci¢city of the recognition was assessed using the irrelevant
preparation scFv A58 as control. The a⁄nity of monoclonal
antibody or scFv 4C1 for the native AahII toxin was meas-
ured by competitive RIA. The KD values deduced from the
data in Fig. 3b as in [23,36] were 0.4 nM (IgG 4C1) and 25
nM (scFv 4C1).
3.4. Neutralization of AahII binding to rat brain synaptosomes
and AahII toxicity in mice by scFv preparations
Scorpion venom is lethal mainly because of AahII binding
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Fig. 3. Immunoreactivity of scFv-4C1 with AahII toxin tested by
RIA. a: Serial dilutions of scFv 4C1 from culture supernatant (¢lled
circle) or periplasmic (open circle) fractions or scFv A58 from cul-
ture supernatant (¢lled triangle) or periplasmic (open triangle) frac-
tions were tested against [125I]AahII. Results are expressed as B/T
where B is the radioactivity bound to antibody and T is total radio-
activity. b: Inhibition of [125I]AahII binding to IgG (open square)
or to scFv-4C1 from culture supernatant preparation (¢lled circle)
was performed with unlabeled AahII. Results are expressed as B/Bo
where B and Bo are the radioactivity bound to antibody in the
presence (B) or absence (Bo) of unlabeled ligand.
Fig. 4. AahII neutralizing capacities of IgG (a) and scFv-4C1 (b).
Binding of [125I]AahII (1U10310 M) to rat brain synaptosomes was
inhibited by incubation with IgG (open square) or periplasmic
(open circle) or culture supernatant (¢lled circle) scFv-4C1 prepara-
tions. Periplasmic (open triangle) and culture supernatant (¢lled tri-
angle) scFv A58 preparations were used as a control. B and Bo are
the binding measured with (B) or without (Bo) IgG or scFv.
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to voltage-dependent sodium channels. The capacity of mono-
clonal antibody 4C1 or scFv 4C1 preparations to inhibit the
e¡ects of AahII was tested in vitro and in vivo. Both mono-
clonal antibody and scFv 4C1 showed dose-dependent inhi-
bition of [125I]AahII binding to its receptor on rat brain syn-
aptosomes (Fig. 4). The irrelevant scFv A58 preparation did
not inhibit binding. Half-maximal inhibition of AahII binding
to synaptosomes was obtained with 1U1039 M IgG 4C1 and
1/600 dilution scFv (10 mg of protein/ml).
The toxicity of AahII was measured in C57BL/6 mice by
i.c.v. injection. The protective e¡ect of scFv was evaluated by
incubating AahII with an equal volume of scFv preparation
and then injecting the mixture i.c.v. The controls contained the
irrelevant scFv A58 preparation at the same protein concen-
tration (5 mg/ml). scFv 4C1 ensured the survival of 50% of the
mice injected after injection of 6 ng of toxin AahII (4 LD50),
whereas all the control mice died (Table 1). The protective
capacity of scFv 4C1 was about 800 LD50 per ml preparation.
The control scFv A58 gave no signi¢cant protection.
4. Discussion and conclusion
Recombinant scFvs are novel agents that may be more
suitable than entire antibodies in certain medical applications,
particularly when they are raised against soluble low molec-
ular weight, di¡usible toxins or tumor antigens [37,38]. This
report describes the successful production of an scFv that
binds to and neutralizes the toxin AahII from scorpion ven-
om. We prepared an scFv from an existing well-characterized
hybridoma rather than from Fv libraries by phage display
technology because phage display often gives scFvs with
poor a⁄nity (1035^1037 M) which are often not soluble
[11,39]. The scFv-4C1 gene was assemble to ensure that the
primary structures of the parent antibody and the recombi-
nant variable regions were the same, even in the priming sites
used for PCR of the variable antibody regions. Sequence dif-
ferences may have an impact on antigen binding, especially
for framework 1 as X-ray structures indicate that the N-ter-
minal extremity of antibodies lies near the CDR loops. Such
mutations may decrease a⁄nity of scFvs compared to their
parent antibody. The recombinant scFv-4C1 was soluble and
retained the structural features that de¢ne the speci¢city of the
parent antibody. The (Gly4Ser)3 linker sequence and reporter
£ag sequences incorporated had no signi¢cant e¡ects on anti-
gen binding. The apparent equilibrium dissociation constant
of the scFv was 25U1039 M, similar to the KD of most anti-
bodies [40]. Thus, scFv-4C1 has a high a⁄nity for AahII. The
recombinant protein was correctly produced without any de-
tectable proteolysis, but the amounts of scFv secreted into the
periplasm and released into the culture medium were quite
low compared to the amount of recombinant protein trapped
in the cytoplasm of the bacteria, mainly as insoluble inclusion
bodies (data not shown). This might be due to such factors as
the host strain, growth conditions, signal sequence and the
structure of this particular scFv. Others have shown that
acid residues at position 1 and 6 of the VH framework 1, as
is the case for scFv-4C1 (E1 and E6), may in£uence the proc-
essing of the exported protein after it has crossed the bacterial
plasma membrane, and its folding e⁄ciency [33,41]. However,
the gene expression system used yielded material of a quality
good enough for the direct, rapid evaluation of recombinant
protein activity.
Bahraoui et al. [23] proposed two possible mechanisms of
neutralization for antibody 4C1: steric hindrance due to the
binding of the whole IgG to the toxin, or an overlap of the
epitope 4C1 with the regions of the toxin that interact with its
acceptor on the presynaptic membrane. This scFv, which is
about 6 times smaller than the whole antibody 4C1, had neu-
tralizing activity. One amino acid residue (K58) of the toxin is
likely implicated in the pharmacological site and also in the
epitope 4C1 [23], therefore we believe that neutralization is
due to an overlap of the two sites. Modelling of the interac-
tions between the toxin whose 3D structure is known and
scFv 4C1 (whose variable domains have been identi¢ed
here) might help to clarify this point. Many high resolution
Fab structures are currently available, so that it should be
possible to prepare a model of the combining site of scFv-
4C1 from its sequence homologies with other antibodies.
In vitro and in vivo experiments indicate that scFv-4C1 has
a high capacity to neutralize the pharmacological e¡ects and
lethal potency of toxin AahII (about 800 LD50 per ml of scFv
preparation by the i.c.v. route). This promises well for the use
of this molecule in detoxication. A scorpion sting must be
treated with a highly di¡usible antivenom, with relatively
high a⁄nity for its target toxin so as to trap the toxin, which
is absorbed rapidly, becomes widely distributed and is slowly
eliminated. scFv ¢ts these requirements well and might be able
to trap the toxin in the vascular and extravascular compart-
ments before it binds to its acceptor. scFv-AahII immuno-
complexes are also small, and can be easily eliminated in
the urine. A production system that provides enough scFv
for detailed neurophysiological and pharmacokinetic studies
must now be developed. A baculovirus system using the same
cloning sites as the pHEN1 vector, as recently reported, may
be suitable for producing large quantities of recombinant
scFv-4C1 in a medium devoid of contaminants toxic for
man in contrast to E. coli, which can release endotoxins [20].
Thus, this report describes the ¢rst fully functional scFv
that actively neutralizes the most potent toxin produced by
the scorpion A. australis which is responsible for many serious
envenomizations and some deaths in North Africa. scFvs are
homogeneous, only slightly immunogenic and di¡use better
than whole IgG or fragments prepared by proteolysis. We
therefore believe that scFv-4C1 is a promising step towards
designing new antivenoms with improved properties for im-
munotherapy.
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